Document is current
Any future updates will be listed below
-
Authors
Friker, Lea L.
Perwein, Thomas
Waha, Andreas
Dörner, Evelyn
Klein, Rebecca
Blattner-Johnson, Mirjam
Layer, Julian P.
Sturm, Dominik
Nussbaumer, Gunther
Kwiecien, Robert
Spier, Isabel
Aretz, Stefan
Kerl, Kornelius
Hennewig, Ulrike
Rohde, Marius
Karow, Axel
Bluemcke, Ingmar
Schmitz, Ann Kristin
Reinhard, Harald
Hernáiz Driever, Pablo
Wendt, Susanne
Weiser, Annette
Guerreiro Stücklin, Ana S.
Gerber, Nicolas U.
von Bueren, André O.
Khurana, Claudia
Jorch, Norbert
Wiese, Maria
Kratz, Christian P.
Eyrich, Matthias
Karremann, Michael
Herrlinger, Ulrich
Hölzel, Michael
Jones, David T. W.
Hoffmann, Marion
Pietsch, Torsten
Gielen, Gerrit H.
Kramm, Christof M.
-
Funding
Funding for this research was provided by:
Niedersächsische Krebsgesellschaft e.V. (Advancement Award 2023, Advancement Award 2023, Advancement Award 2023)
Medical Faculty of the University of Bonn, Bonn, Germany (2022–1A-09)
German Federal Ministry of Education and Research (01GM2205A)
Deutsche Kinderkrebsstiftung (DKS 2024.03)
Universitätsklinikum Bonn
- License Information
-
More Information
Article History
Received: 13 November 2024
Revised: 6 January 2025
Accepted: 7 January 2025
First Online: 2 February 2025
Declarations
:
: U.H. received advisory board and speaker honoraria from Medac and Bayer, and advisory board honoraria from Servier and Oncomagnetx. All other authors declare no conflicts of interest.
: The HIT-HGG-2013 trial (NCT03243461) was approved by the Ethics Committee of the University Medical Center Göttingen, Göttingen, Germany (222/23-EP). The INFORM (S-502/2013) and MNP2.0 (S-320/2014) studies were approved by the Ethics Committee of the Medical Faculty Heidelberg, Heidelberg, Germany. Each participant or each participant's guardian gave written informed consent for participation in the respective trial.
